drugset / Trial / NCT05519839
A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine
RandomizedParallel-groupTriple-blindPrevention
Summary
This is a randomized, observer-blinded, Phase 2 study evaluating the safety and immunogenicity of a severe acute respiratory syndrome coronavirus 2 (SARSCoV2) recombinant spike (rS) (SARS-CoV-2 rS) nanoparticle and quadrivalent hemagglutinin (HA) nanoparticle influenza vaccine (qNIV) combination vaccine with Matrix-M™ adjuvant; this combination vaccine.
Timeline
- Start
- 2022-12-30
- Primary completion
- 2023-07-25
- Completion
- 2023-12-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CIC Vaccine with Matrix-M Adjuvant | Vaccine | — | Intramuscular |
| Subject | Influenza Virus Vaccine | Vaccine | — | Intramuscular |
| Subject | SARS-CoV-2 rS Vaccine with Matrix-M Adjuvant | Vaccine | — | Intramuscular |
| Subject | qNIV Vaccine with Matrix-M Adjuvant | Vaccine | — | Intramuscular |